A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after 1 year

Journal of Clinical Psychiatry

Volumn 63, Issue 5, 2002, Pages 425-433

  Meyer, Jonathan M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; LIPID; LITHIUM; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 0036252327     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0509     Document Type: Article

References (98)

1. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States
2. Psychopharmacology, from chlorpromazine to olanzapine: A brief history of antipsychotics
3. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
4. The pharmacoeconomics of clozapine: A review
5. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
6. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
7. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials
8. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
9. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study
10. The cognitive efficacy of atypical antipsychotics in schizophrenia
11. Zeldox (ziprasidone hydrochloride capsules) NDA 20-825 [briefing document; Pfizer]
12. Novel antipsychotics and new onset diabetes
13. Olanzapine increases weight and serum triglycerides
14. Olanzapine-induced elevation of plasma triglyceride levels
15. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
16. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
17. Atypical antipsychotics and weight gain: A systematic review
18. Weight changes in patients treated with quetiapine
19. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
20. Weight gain from novel antipsychotic drugs: Need for action
21. Glucose intolerance with atypical antipsychotics
22. Novel antipsychotics and severe hyperlipidemia
23. Risperidone-associated new-onset diabetes
24. The disease burden associated with overweight and obesity
25. Effects of caloric restriction on behavior and body weight during chlorpromazine therapy
26. Weight reduction with chlorphentermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy
27. Reinforcement and weight loss in schizophrenics
28. Weight reduction in schizophrenics by molindone
29. The effect of antipsychotic drugs on body weight: A retrospective review
30. Weight gain and prolactin levels in patients on long-term antipsychotic medication: A double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate
31. Induction of obesity by psychotropic drugs
32. Prevalence of obesity in patients receiving depot antipsychotics
33. Weight gain associated with neuroleptic medication: A review
34. The distribution of body mass index among individuals with and without schizophrenia
35. Compliance with antipsychotic drug treatment: Influence of side effects
36. Obesity as a risk factor for antipsychotic noncompliance
37. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
38. High diabetes frequency in schizophrenia and bipolar disorder
39. Prevalence and correlates of diabetes in national schizophrenia samples
40. Glucose-induced increase in memory performance in patients with schizophrenia
41. Glucose regulation during antipsychotic treatment in schizophrenia
42. Diabetic ketoacidosis associated with clozapine treatment
43. Severe hyperglycemia associated with high doses of clozapine
44. Ketoacidosis as a side-effect of clozapine: A case report
45. Clozapine and associated diabetes mellitus
46. Olanzapine-induced ketoacidosis with diabetes mellitus
47. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
48. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
49. The effect of clozapine on glucose metabolism
50. Antipsychotics linked to weight gain, diabetes
51. Diabetic ketoacidosis associated with clozapine treatment
52. Hyperglycemia in patients treated with olanzapine
53. Prevalence of diabetes during extended clozapine and olanzapine treatment
54. Differential effects of antipsychotics on type II diabetes: Findings from a large health plan database
55. Olanzapine-induced hyperglycemic nonketonic coma
56. New onset diabetes and atypical antipsychotics
57. Atypical antipsychotics and hyperglycaemia
58. Group treatment for smoking cessation among persons with schizophrenia
59. The effect of three butyrophenones on serum cholesterol levels
60. Further studies on the effect of butyrophenones on cholesterol synthesis in humans
61. Lipids and apolipoproteins in patients treated with major tranquilizers
62. Clozapine-associated elevation in serum triglycerides
63. The apparent effects of ziprasidone on plasma lipids and glucose
64. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia
65. Rehabilitation of frontal/executive impairments in schizophrenia
66. Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia
67. Mortality in a cohort of patients with schizophrenia: A record linkage study
68. Excess mortality of mental disorder
69. The treatment of unrelated disorders in patients with chronic medical diseases
70. Smoking cessation treatment for patients with schizophrenia
71. Mental disorders and use of cardiovascular procedures after myocardial infarction
72. Mortality and causes of death in schizophrenia in Stockholm county, Sweden
73. Differential effect of clozapine on weight: A controlled study
74. Dosing the antipsychotic medication olanzapine
75. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
76. Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials
77. Novel antipsychotics: Comparison of weight gain liabilities
78. Antipsychotic-induced weight gain: A comprehensive research synthesis
79. Risperidone versus haloperidol for prevention of relapse in schizophrenia
80. Body weight and leptin plasma levels during treatment with antipsychotic drugs
81. Obesity: What mental health professionals need to know
82. Serum lipids in epileptic children treated with carbamazepine and valproate
83. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants
84. Serum lipids, lipoproteins, and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid, or phenytoin
85. Does long-term lithium treatment induce diabetes mellitus?
86. The effect of short term lithium carbonate in type 2 diabetes mellitus
87. The spread of the obesity epidemic in the United States, 1991-1998
88. Atypical antipsychotics and cardiovascular risk in schizophrenic patients
89. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia
90. Risperidone in the treatment of elderly patients with psychotic disorders
91. The efficacy, safety, and tolerability of antipsychotics in the elderly
92. Long-term quetiapine treatment for psychosis in patients with Parkinson's disease who failed treatment with other atypical antipsychotics
93. Epidemiology of hypertriglyceridemia and cardiovascular disease
94. Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
95. Hyperglycemia and ketoacidosis associated with olanzapine
96. Executive summary of the 3rd report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 3)
97. Screening for diabetes